Liquid Biopsy Market Size & Share, by Product (Tools, Assay Kits & Reagents, Services); Biomarker Type (Circulating Tumor Cells, Circulating Tumor DNA, Exosomes, Circulating RNA & Proteins); Sample (Blood, Urine); Disease Indication (Lung, Colorectal); Clinical Application (Early Disease Screening, Molecular Health Monitoring); End-Users - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 69
  • Published Date: Oct 03, 2024
  • Report Format: PDF, PPT

Global Liquid Biopsy Market TOC

  1. Market Definition
    1. Market Definition
    2. Market Segmentation
    3. Product Overview
  2. Research Methodology
    1. Research Process
    2. Primary Research
      1. Manufacturers
      2. End-users
    3. Secondary research
    4. Market size estimation
  3. Executive Summary- Global Liquid Biopsy Market
  4. Analysis of Market Dynamics
    1. Drivers
    2. Restraints
    3. Opportunities
    4. Trends
  5. Regulatory & Standards Landscape
  6. Pricing Analysis
  7. Epidemiology Analysis
  8. Impact of COVID-19 on the Liquid Biopsy Market
    1. Pre-COVID-19 Scenario, 2017-19
    2. COVID-19 scenario, 2020
    3. Post-COVID-19 scenario
  9. Comparative Analysis (Liquid biopsy vs Tissue-based biopsy)
  10. End-User Usability Analysis
  11. Competitive Structure
  12. Global Liquid Biopsy Market Outlook
    1. Global Liquid Biopsy Market Segmentation Analysis 2019-2028
      1. By Product, 2019-2028F (in USD Million)
        1.                           Tools, 2019-2028F (USD Million)
          1. Next generation sequencing (NGS), 2019-2028F (USD Million)
          2. Polymerase chain reaction (PCR), 2019-2028F (USD Million)
          3. Microarrays, 2019-2028F (USD Million)
        2. Assay kits & reagents, 2019-2028F (USD Million)
        3. Services, 2019-2028F (USD Million)
      2. By Biomarker Type, 2019-2028F (in USD Million)
        1. Circulating Tumor Cells, 2019-2028F (USD Million)
        2. Circulating Tumor DNA, 2019-2028F (USD Million)
        3. Exosomes, 2019-2028F (USD Million)
        4. Circulating RNA & Proteins, 2019-2028F (USD Million)
        5. Nucleosomes, 2019-2028F (USD Million)
      3. By Sample, 2019-2028F (in USD Million)
        1. Blood, 2019-2028F (USD Million)
        2. Urine, 2019-2028F (USD Million)
        3. Others, 2019-2028F (USD Million)
      4. By Clinical Application, 2019-2028F (in USD Million)
        1. Early Disease Screening, 2019-2028F (USD Million)
        2. Therapy Selection, 2019-2028F (USD Million)
        3. Treatment Response Monitoring, 2019-2028F (USD Million)
        4. Molecular Health Monitoring, 2019-2028F (USD Million)
        5. Others, 2019-2028F (USD Million)
      5. By Disease Indication, 2019-2028F (in USD Million)
        1. Lung Cancer, 2019-2028F (USD Million)
        2. Colorectal Cancer, 2019-2028F (USD Million)
        3. Breast Cancer, 2019-2028F (USD Million)
        4. Prostate Cancer, 2019-2028F (USD Million)
        5. Liver Cancer, 2019-2028F (USD Million)
        6. Head & Neck Cancer, 2019-2028F (USD Million)
        7. Others, 2019-2028F (USD Million)
      6. By End-User, 2019-2028F (in USD Million)
        1. Hospitals, 2019-2028F (USD Million)
        2. Clinics, 2019-2028F (USD Million)
        3. Research Laboratories, 2019-2028F (USD Million)
        4. Academic Institutes, 2019-2028F (USD Million)
        5. Others, 2019-2028F (USD Million)
      7. By Region, 2019-2028F (in USD Million)
        1. North America, 2019-2028F (in USD Million)
        2. Europe, 2019-2028F (in USD Million)
        3. Asia Pacific, 2019-2028F (in USD Million)
        4. Latin America, 2019-2028F (in USD Million)
        5. Middle East & Africa, 2019-2028F (in USD Million)
  13. North America Liquid Biopsy Market Outlook
    1. North America Liquid Biopsy Market Segmentation Analysis 2019-2028
      1. By Product, 2019-2028F (in USD Million)
      2. By Biomarker Type, 2019-2028F (in USD Million)
      3. By Sample, 2019-2028F (in USD Million)
      4. By Clinical Application, 2019-2028F (in USD Million)
      5. By Disease Indication, 2019-2028F (in USD Million)
      6. By End-User, 2019-2028F (in USD Million)
      7. By Country, 2019-2028F (in USD Million)
  14. Latin America Liquid Biopsy Market Outlook
    1. Latin America Liquid Biopsy Market Segmentation Analysis 2019-2028
      1. By Product, 2019-2028F (in USD Million)
      2. By Biomarker Type, 2019-2028F (in USD Million)
      3. By Sample, 2019-2028F (in USD Million)
      4. By Clinical Application, 2019-2028F (in USD Million)
      5. By Disease Indication, 2019-2028F (in USD Million)
      6. By End-User, 2019-2028F (in USD Million)
      7. By Country, 2019-2028F (in USD Million)
  15. Europe Liquid Biopsy Market Outlook
    1. Europe Liquid Biopsy Market Segmentation Analysis 2019-2028
      1. By Product, 2019-2028F (in USD Million)
      2. By Biomarker Type, 2019-2028F (in USD Million)
      3. By Sample, 2019-2028F (in USD Million)
      4. By Clinical Application, 2019-2028F (in USD Million)
      5. By Disease Indication, 2019-2028F (in USD Million)
      6. By End-User, 2019-2028F (in USD Million)
      7. By Country, 2019-2028F (in USD Million)
  16. Asia Pacific Liquid Biopsy Market Outlook
    1. Asia Pacific Liquid Biopsy Market Segmentation Analysis 2019-2028
      1. By Product, 2019-2028F (in USD Million)
      2. By Biomarker Type, 2019-2028F (in USD Million)
      3. By Sample, 2019-2028F (in USD Million)
      4. By Clinical Application, 2019-2028F (in USD Million)
      5. By Disease Indication, 2019-2028F (in USD Million)
      6. By End-User, 2019-2028F (in USD Million)
      7. By Country, 2019-2028F (in USD Million)
  17. Middle East & Africa Liquid Biopsy Market Outlook
    1. Middle East & Africa Liquid Biopsy Market Segmentation Analysis 2019-2028
      1. By Product, 2019-2028F (in USD Million)
      2. By Biomarker Type, 2019-2028F (in USD Million)
      3. By Sample, 2019-2028F (in USD Million)
      4. By Clinical Application, 2019-2028F (in USD Million)
      5. By Disease Indication, 2019-2028F (in USD Million)
      6. By End-User, 2019-2028F (in USD Million)
      7. By Country, 2019-2028F (in USD Million)
  18. Competitive Structure
    1. Qiagen
    2. F. Hoffmann-La Roche Ltd
    3. Bio-Rad Laboratories, Inc.
    4. Illumina, Inc.
    5. Inivata Limited
    6. Agena Bioscience, Inc.
    7. Thermo Fisher Scientific
    8. Guardant Health, Inc.

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Liquid Biopsy Market size was valued at USD 5.96 billion in 2023 and is expected to reach USD 26.93 billion by 2036, expanding at around 12.3% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of liquid biopsy is evaluated at USD 6.55 billion.

The growth of the liquid biopsy market can be attributed to the increasing advancements in medical research, as well as the rising concern for the increasing prevalence of chronic diseases worldwide. Global cancer incidences are on the rise, with breast cancer being the most prevalent among all cancers. The increase in cancer occurrences drives technological advances for diagnostic and treatment fields to ensure cancer detection and treatment and decrease the mortality rates. All cancers release various cells, genetic material, and other cellular components into the bloodstream that can be used to detect specific markers to diagnose them. Liquid biopsy has seen significant advancements in technology and a rise in its clinical and research application. While tissue biopsy remains the gold standard in cancer diagnosis and treatment, liquid biopsy in conjunction with other diagnostic approaches can be vital in diagnosing cancers as treatment at an early stage has a higher probability of cure. According to the statistical report GLOBOCAN 2020 released by the International Agency for Research on Cancer (IARC), stated that in the year 2020, a total of 19.3 Million cancer cases were registered globally. Moreover, a total of 10 Million deaths caused due to cancer was also registered in the same year.

Furthermore, tremendous progress has been made in all medicine sectors, both diagnostic and curative, in the global healthcare system. The advancement of non-invasive or minimally invasive therapies, more precise diagnostics employing artificial intelligence, and telemedicine breakthroughs are paving the way for better infrastructure with composite solutions for diverse conditions at an accessible price. However, due to a lack of regulatory standards in particular developing countries and other policies that prohibit the use of liquid biopsy in hospitals, liquid biopsy remains minimal. As a result, only a few hospitals and research institutions utilize liquid biopsy, which is expected to hamper the liquid biopsy market growth during the forecast period. 


Liquid Biopsy Market Overview
Get more information on this report: Request Free Sample PDF

Liquid Biopsy Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Incidence of Cancer
  • Increasing Research and Developments in Diagnostic Technologies

Challenges

  • Changing Regulatory Standards Associated with Biopsy
  • Preference for Alternative Types of Biopsy

Liquid Biopsy Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

12.3%

Base Year Market Size (2023)

USD 5.96 billion

Forecast Year Market Size (2036)

USD 26.93 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, South Korea, Malaysia, Australia, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Liquid Biopsy Segmentation

The global liquid biopsy market is segmented by product type into tools, assay kits & reagents, and services. Amongst these segments, the tools segment is estimated to hold the highest share of 66% in 2021. The tools segment is further estimated to achieve a revenue of USD 2481.3 Million in 2021 and further garner 66.20% share by the end of 2036. Further, the market is segmented by samples into blood, urine, and others, out of which, the blood segment is expected to hold a significant market share throughout the forecast period, as the liquid biopsy process is usually conducted using blood samples. The market is further segmented by end user into hospitals, clinics, research laboratories, academic institutes, and others. Out of these, the hospitals segment is projected to gain the largest share of around 41% during the forecast period. Based on disease indication, the market is segmented into lung, colorectal, breast, prostate, liver, and head & neck cancers, and others. Out of these, the breast cancer segment is estimated to garner the highest market revenue by the end of 2028, owing to the growing incidence of breast cancer among women has led to many challenges for its treatment on account of its complexity in nature.  The breast cancer segment is estimated to attain revenue of USD 908.3 Million in 2021 and further garner USD 6703.1 Million in 2028.


Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Liquid Biopsy Industry - Regional Synopsis

Regionally, the global market is segmented into five major regions, which include North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America industry is expected to hold largest revenue share of 36% by 2036. The market in the region is further expected to grow at a CAGR of 29.7% during the forecast period. On the other hand, the Europe liquid biopsy market is projected to hold second leading stance by garnering a revenue of USD 1228.8 Million in 2021. The growth of the market in the region can be attributed to the rising healthcare expenditure in the major countries of Europe, such as Germany, UK, Spain, and Russia.

Furthermore, in the North American region, the United States is projected to generate significant growth opportunities for market growth by attaining a revenue of 1284.3 USD Million in 2021, while Canada is projected to reap 154.4 USD Million in revenue during the same year. The North American market presently captures the larger share due to the region's robust healthcare infrastructure. Additionally, the growing prevalence of cancer in the region is also expected to generate massive demand for liquid biopsy over the forecast period. Moreover, the increasing initiatives by the U.S. government to upgrade the facilities in cancer care is also expected to favor the market's growth in the coming years. Furthermore, improved research infrastructure and increasing investments in R&D in the healthcare industry alongside the initiatives taken by the U.S. government are some of the other factors expected to contribute to the growth of the market. Over the years, government spending on healthcare resources has significantly increased the regulatory landscape, which is also a prominent factor driving the market's growth.

Get more information on this report: Request Free Sample PDF

Companies Dominating the Liquid Biopsy Landscape

    • Qiagen
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • F. Hoffmann-La Roche Ltd
    • Bio-Rad Laboratories, Inc.
    • Illumina, Inc.
    • Inivata Limited
    • Agena Bioscience, Inc.
    • Thermo Fisher Scientific
    • Guardant Health, Inc

In the News

  • In February 2021, Thermo Fisher Scientific Inc. announced that it had acquired the point-of-care molecular diagnostic company, Mesa Biotech, Inc. The deal would allow Thermo Fisher to ring much needed diagnostics to the market.
  • In June 2020, Inivata Limited announced that their strategic partner NeoGenomics, Inc., in the United States, has launched InVisionFirst-Lung liquid biopsy commercially. The test is FDA-approved and covers all National Comprehensive Cancer Network (NCCN) guidelines. The launch of the test would also allow the company in expanding its geographical presence and promoting its products in other countries.
  • In March 2019, Guardant Health, Inc. announced that it would acquire Bellwether Bio, Inc. and the transaction is projected to close by April 2019. The acquisition would help Guardant Health to enhance their product pipeline in the future.

Author Credits:  Radhika Pawar


  • Report ID: 69
  • Published Date: Oct 03, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing incidence of cancer and, rising research and development activities are the major factors responsible for the growth of the market.

The market is anticipated to attain a CAGR of 30.7% over the forecast period i.e., 2020-2028.

High regulatory standards associated with biopsy procedures is estimated to act as barriers to the market growth.

Asia Pacific is estimated to create notable growth opportunities for market growth over the forecast period.

The major players in the market are Qiagen, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Illumina, Inc., Inivata Limited, Agena Bioscience, Inc., Thermo Fisher Scientific, Guardant Health, Inc. and others.
Liquid Biopsy Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample